RNA · Company research
Atrium Therapeutics, Inc. Common Stock (RNA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
14records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| RNA: Atrium Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits | RNA: Atrium Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| Atrium Therapeutics Announces $50 Million Private Placement - Stock Titan | Atrium Therapeutics Announces $50 Million Private Placement Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| Avidity Biosciences misses HARBOR endpoint: analysts target RNA stock at USD 63.75 - ad-hoc-news.de | Avidity Biosciences misses HARBOR endpoint: analysts target RNA stock at USD 63.75 ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 6, 2026 | neutral | 0 | 0.6 |
| GSK continues to stock up on Wave's RNA drugs with liver-focused program - Fierce Biotech | GSK continues to stock up on Wave's RNA drugs with liver-focused program Fierce Biotech | View source ↗ | Fierce Biotech | Sep 30, 2026 | neutral | 0 | 0.6 |
| 4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - Zacks Investment Research | 4 RNA Therapeutics Stocks Leading the Next Wave of Innovation Zacks Investment Research | View source ↗ | Zacks Investment Research | Sep 28, 2026 | neutral | 0 | 0.6 |
| One new hire gets 13,500 options and 6,750 stock units from Atrium Therapeutics - Stock Titan | One new hire gets 13,500 options and 6,750 stock units from Atrium Therapeutics Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Wave Life Sciences: An Fairly Valued RNA Opportunity - Seeking Alpha | Wave Life Sciences: An Fairly Valued RNA Opportunity Seeking Alpha | View source ↗ | Seeking Alpha | Aug 12, 2026 | neutral | 0 | 0.6 |
| Is Wave Life Sciences (WVE) Undervalued Or Is Its RNA Pipeline Already Priced In? - Simply Wall Street | Is Wave Life Sciences (WVE) Undervalued Or Is Its RNA Pipeline Already Priced In? Simply Wall Street | View source ↗ | Simply Wall Street | Jul 22, 2026 | neutral | 0 | 0.6 |
| RNA Forecast — Price Target — Prediction for 2027 - TradingView | RNA Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation - Yahoo Finance | Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation Yahoo Finance | View source ↗ | Yahoo Finance | May 28, 2026 | neutral | 0 | 0.6 |
| Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions - MedCity News | Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions MedCity News | View source ↗ | MedCity News | Mar 1, 2026 | neutral | 0 | 0.6 |
| Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off - Trefis | Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off Trefis | View source ↗ | Trefis | Feb 28, 2026 | neutral | 0 | 0.6 |
| $RNA stock is down 80% today. Here's what we see in our data. | RNA Stock News - Quiver Quantitative | $RNA stock is down 80% today. Here's what we see in our data. | RNA Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Feb 27, 2026 | neutral | 0 | 0.6 |
| Avidity Biosciences Announces Expected Record Date for Spin-Off - PR Newswire | Avidity Biosciences Announces Expected Record Date for Spin-Off PR Newswire | View source ↗ | PR Newswire | Feb 2, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.